IL176473A - 3 (2h) - pyridazinone for use as a neutrophil inhibitor - Google Patents

3 (2h) - pyridazinone for use as a neutrophil inhibitor

Info

Publication number
IL176473A
IL176473A IL176473A IL17647306A IL176473A IL 176473 A IL176473 A IL 176473A IL 176473 A IL176473 A IL 176473A IL 17647306 A IL17647306 A IL 17647306A IL 176473 A IL176473 A IL 176473A
Authority
IL
Israel
Prior art keywords
piridazinone
neutrophilia
inhibitor
neutrophilia inhibitor
Prior art date
Application number
IL176473A
Other languages
English (en)
Hebrew (he)
Other versions
IL176473A0 (en
Inventor
Takehisa Iwama
Nobutomo Tsuruzoe
Original Assignee
Nissan Chemical Ind Ltd
Taisho Pharmaceutical Co Ltd
Takehisa Iwama
Nobutomo Tsuruzoe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd, Taisho Pharmaceutical Co Ltd, Takehisa Iwama, Nobutomo Tsuruzoe filed Critical Nissan Chemical Ind Ltd
Publication of IL176473A0 publication Critical patent/IL176473A0/en
Publication of IL176473A publication Critical patent/IL176473A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IL176473A 2003-12-26 2006-06-21 3 (2h) - pyridazinone for use as a neutrophil inhibitor IL176473A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003433747 2003-12-26
PCT/JP2004/019199 WO2005063250A1 (ja) 2003-12-26 2004-12-22 好中球増多抑制剤

Publications (2)

Publication Number Publication Date
IL176473A0 IL176473A0 (en) 2006-10-05
IL176473A true IL176473A (en) 2013-06-27

Family

ID=34736527

Family Applications (1)

Application Number Title Priority Date Filing Date
IL176473A IL176473A (en) 2003-12-26 2006-06-21 3 (2h) - pyridazinone for use as a neutrophil inhibitor

Country Status (12)

Country Link
US (2) US20070117806A1 (enExample)
EP (1) EP1698339A4 (enExample)
JP (1) JP4688681B2 (enExample)
KR (2) KR101293350B1 (enExample)
CN (1) CN1897952B (enExample)
AU (1) AU2004308806B9 (enExample)
BR (1) BRPI0417200A (enExample)
CA (1) CA2549672C (enExample)
IL (1) IL176473A (enExample)
RU (1) RU2356555C2 (enExample)
TW (1) TW200522962A (enExample)
WO (1) WO2005063250A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101538245B (zh) * 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
CN102133217B (zh) * 2010-01-27 2013-07-24 中国科学院上海药物研究所 一类以n为桥键的哒嗪酮类化合物在制备抗肿瘤的药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149761T3 (es) * 1990-04-25 2000-11-16 Nissan Chemical Ind Ltd Derivado de piridazinona.
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
DK1025847T3 (da) * 1997-08-28 2006-02-13 Nissan Chemical Ind Ltd Neovaskulariseringspromotorer og neovaskulariseringsforstarkere
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
RU2229297C2 (ru) * 1998-09-01 2004-05-27 Ниссан Кемикал Индастриз, Лтд. Терапевтический агент для лечения стеноза позвоночного канала
GB9824160D0 (en) * 1998-11-04 1998-12-30 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
CA2353956C (en) * 1998-12-07 2008-10-28 Nissan Chemical Industries, Ltd. Remedial agent for erectile dysfunction
ES2215631T3 (es) * 1999-03-23 2004-10-16 Hollis-Eden Pharmaceuticals Inc. Hemihidrato de 16alfa-bromoepiandrosterona.
JP2001131088A (ja) * 1999-11-02 2001-05-15 Kyurin:Kk シンドロームｘ症候群治療剤

Also Published As

Publication number Publication date
TW200522962A (en) 2005-07-16
TWI341729B (enExample) 2011-05-11
CA2549672C (en) 2010-06-22
IL176473A0 (en) 2006-10-05
KR20060125816A (ko) 2006-12-06
RU2356555C2 (ru) 2009-05-27
US20070117806A1 (en) 2007-05-24
KR20100019542A (ko) 2010-02-18
KR101293350B1 (ko) 2013-08-05
AU2004308806B2 (en) 2009-10-29
RU2006127040A (ru) 2008-02-10
EP1698339A1 (en) 2006-09-06
WO2005063250A1 (ja) 2005-07-14
AU2004308806A1 (en) 2005-07-14
CN1897952A (zh) 2007-01-17
JPWO2005063250A1 (ja) 2007-07-19
BRPI0417200A (pt) 2007-02-06
JP4688681B2 (ja) 2011-05-25
US20080306080A1 (en) 2008-12-11
CN1897952B (zh) 2010-12-08
AU2004308806B9 (en) 2010-01-28
CA2549672A1 (en) 2005-07-14
HK1098378A1 (en) 2007-07-20
EP1698339A4 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
TWI341314B (en) New compounds
EG25482A (en) Inhibitors
IL177933A0 (en) New compounds
IL166650A0 (en) New compounds
AU2003264018A8 (en) New compounds
IL163894A0 (en) New compounds
GB0329667D0 (en) Core 2 GlcNAc-T inhibitor
HU0203976D0 (en) New compounds
AU153838S (en) A sofa
GB2406533B (en) Stage for a workpiece
HRP20050162A2 (en) ?-lactamase inhibitor prodrug
GB0305202D0 (en) Scale inhibitor
GB0214344D0 (en) New odorant Compounds
EP1627064A4 (en) INHIBITION OF FLOWER
GB0200271D0 (en) A carrying aid
IL176473A0 (en) Neutrophilia inhibitor
GB0309120D0 (en) A set of parts
GB0316773D0 (en) A tool
PL113425U1 (en) Appliance for pulling out ticks
GB0219365D0 (en) A vice
GB0319498D0 (en) Core 2 GlcNAc-T Inhibitor
GB0313361D0 (en) Core 2 Glcnac-T inhibitor
GB0212426D0 (en) Core 2 GlcNac-T Inhibitor
GB0305525D0 (en) Inhibitor based sequencing technology
GB0206465D0 (en) A set of parts

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees